For open-angle glaucoma or ocular hypertension. Sold as Zioptan. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Tafluprost (sold as Zioptan), first approved Feb 10, 2012, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Retinal Ganglion Cell Neuroprotection Under Prostaglandin AnaloguesGlaucoma · Association for Innovation and Biomedical Research on Light and Image | — | Not yet recruiting | Jul 20, 2025 |
| Feb 10, 2012 | ZioptanNDA 202514 · New molecular entity | Thea Pharma | 5 | Marketed |
| Aug 19, 2019 | TafluprostANDA 209051 | Micro Labs | 1 | Marketed |
| Jan 28, 2022 | TafluprostANDA 209040 | Sandoz | 1 | Marketed |
| Apr 5, 2024 | TafluprostANDA 218002 | Ingenus Pharms LLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sandoz